HRP20151396T1 - Mutanti adenovirusa e1a i e1b selektivni za tumore - Google Patents

Mutanti adenovirusa e1a i e1b selektivni za tumore Download PDF

Info

Publication number
HRP20151396T1
HRP20151396T1 HRP20151396T HRP20151396T HRP20151396T1 HR P20151396 T1 HRP20151396 T1 HR P20151396T1 HR P20151396 T HRP20151396 T HR P20151396T HR P20151396 T HRP20151396 T HR P20151396T HR P20151396 T1 HRP20151396 T1 HR P20151396T1
Authority
HR
Croatia
Prior art keywords
pea3
functional part
site
binding site
nucleotides
Prior art date
Application number
HRP20151396T
Other languages
English (en)
Croatian (hr)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HRP20151396T1 publication Critical patent/HRP20151396T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HRP20151396T 2009-03-02 2010-03-02 Mutanti adenovirusa e1a i e1b selektivni za tumore HRP20151396T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02
EP10749205.0A EP2403951B1 (en) 2009-03-02 2010-03-02 Tumor-selective adenovirus e1a and e1b mutants
PCT/US2010/025926 WO2010101921A2 (en) 2009-03-02 2010-03-02 Tumor-selective e1a and e1b mutants

Publications (1)

Publication Number Publication Date
HRP20151396T1 true HRP20151396T1 (hr) 2016-03-25

Family

ID=42710189

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20151396T HRP20151396T1 (hr) 2009-03-02 2010-03-02 Mutanti adenovirusa e1a i e1b selektivni za tumore
HRP20191808TT HRP20191808T1 (hr) 2009-03-02 2019-10-03 Mutanti tumorsko-selektivnih adenovirusa e1a i e1b

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191808TT HRP20191808T1 (hr) 2009-03-02 2019-10-03 Mutanti tumorsko-selektivnih adenovirusa e1a i e1b

Country Status (15)

Country Link
US (6) US9073980B2 (enExample)
EP (4) EP4123030A1 (enExample)
JP (5) JP6072414B2 (enExample)
KR (4) KR102020018B1 (enExample)
CY (1) CY1122385T1 (enExample)
DK (2) DK2403951T3 (enExample)
ES (2) ES2750305T3 (enExample)
HR (2) HRP20151396T1 (enExample)
HU (2) HUE026386T2 (enExample)
LT (1) LT3029144T (enExample)
PL (2) PL2403951T3 (enExample)
PT (2) PT2403951E (enExample)
SI (2) SI3029144T1 (enExample)
SM (2) SMT201900565T1 (enExample)
WO (1) WO2010101921A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2403951T3 (en) 2009-03-02 2016-01-11 Univ California Tumor-selective E1a and E1b adenoviral mutants
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3022320B2 (en) 2013-07-19 2024-09-25 Ludwig Institute for Cancer Research Ltd Whole-genome and targeted haplotype reconstruction
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CN110741081B (zh) * 2017-01-30 2024-07-23 埃皮辛特瑞柯斯公司 肿瘤选择性tata盒和caat盒突变体
CA3052090A1 (en) * 2017-01-30 2018-08-02 Epicentrx, Inc. Multiple transgene recombinant adenovirus
AU2018253088B2 (en) * 2017-04-10 2024-09-19 Epicentrx, Inc. Method for producing recombinant virus
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
MX2019014059A (es) * 2017-05-24 2020-07-28 Epicentrx Inc Adenovirus antiangiogenico.
KR102702230B1 (ko) 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
KR102757384B1 (ko) 2017-09-27 2025-01-20 에피센트알엑스, 인코포레이티드 면역조절 융합 단백질
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3844286A1 (en) * 2018-08-31 2021-07-07 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells
US12680122B2 (en) 2019-10-08 2026-07-14 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof
CN118931897B (zh) * 2024-06-27 2026-01-16 中山大学 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
PT1135514E (pt) * 1999-01-28 2009-07-20 Onyx Pharma Inc Vectores de vaivém adenovirais com deleção em e1b
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
US6884613B2 (en) * 2000-08-25 2005-04-26 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
WO2005052143A2 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
JP5484897B2 (ja) * 2007-04-20 2014-05-07 タカラバイオ株式会社 遺伝子治療のためのベクター
DK2403951T3 (en) 2009-03-02 2016-01-11 Univ California Tumor-selective E1a and E1b adenoviral mutants

Also Published As

Publication number Publication date
KR102150027B1 (ko) 2020-10-26
ES2750305T3 (es) 2020-03-25
US20250327037A1 (en) 2025-10-23
SI3029144T1 (sl) 2019-11-29
US11618888B2 (en) 2023-04-04
US20110318311A1 (en) 2011-12-29
US12195766B2 (en) 2025-01-14
JP6375273B2 (ja) 2018-08-15
JP6072414B2 (ja) 2017-02-01
HUE026386T2 (en) 2016-06-28
SMT201500329B (it) 2016-02-25
US9073980B2 (en) 2015-07-07
EP3591059B1 (en) 2022-07-20
EP3591059A1 (en) 2020-01-08
ES2557812T3 (es) 2016-01-28
PL2403951T3 (pl) 2016-04-29
JP7326396B2 (ja) 2023-08-15
EP3029144B1 (en) 2019-07-10
JP6817979B2 (ja) 2021-01-20
LT3029144T (lt) 2019-10-25
DK3029144T3 (da) 2019-10-21
DK2403951T3 (en) 2016-01-11
US10876097B2 (en) 2020-12-29
KR20190104643A (ko) 2019-09-10
JP2016028035A (ja) 2016-02-25
SI2403951T1 (sl) 2016-04-29
KR20180049188A (ko) 2018-05-10
US20160017294A1 (en) 2016-01-21
EP3029144A1 (en) 2016-06-08
CY1122385T1 (el) 2021-01-27
KR101752910B1 (ko) 2017-06-30
JP2022023074A (ja) 2022-02-07
PT3029144T (pt) 2019-10-28
EP2403951B1 (en) 2015-09-30
EP4123030A1 (en) 2023-01-25
JP2020078326A (ja) 2020-05-28
PL3029144T3 (pl) 2020-06-01
US20190136204A1 (en) 2019-05-09
WO2010101921A2 (en) 2010-09-10
JP2012519014A (ja) 2012-08-23
HUE046565T2 (hu) 2020-03-30
KR20110122866A (ko) 2011-11-11
KR102020018B1 (ko) 2019-09-09
EP2403951A4 (en) 2012-08-22
KR101922539B1 (ko) 2018-11-27
EP2403951A2 (en) 2012-01-11
HRP20191808T1 (hr) 2019-12-27
SMT201900565T1 (it) 2019-11-13
WO2010101921A3 (en) 2011-01-06
JP2018113971A (ja) 2018-07-26
US20210171917A1 (en) 2021-06-10
US20230272349A1 (en) 2023-08-31
KR20170077278A (ko) 2017-07-05
PT2403951E (pt) 2016-01-29

Similar Documents

Publication Publication Date Title
HRP20191808T1 (hr) Mutanti tumorsko-selektivnih adenovirusa e1a i e1b
DK2875043T3 (en) glucagon
Jeffers et al. A novel human fibroblast growth factor treats experimental intestinal inflammation
CL2011000013A1 (es) Polipeptido factor estimulante de colonias de granulocitos bovino (bg-csf) que comprende uno o mas aminoacidos no codificados de manera natural; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno modulado por bg-csf.
AU2010246273B2 (en) Compositions and methods for enhancing antigen-specific immune responses
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
HRP20191852T1 (hr) Polipeptidi
EP3046573A2 (en) Amylin analogues
BR112013007385A2 (pt) leptinas altamente solúveis
KR102147721B1 (ko) 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물
CN105939723A (zh) 前列腺癌治疗用组合物
HK1249433A1 (zh) 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途
US20190328801A1 (en) Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes p8 protein, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same
JP2007511212A5 (enExample)
JP5435871B2 (ja) Ｅ１−マイナスアデノウイルス及びその使用
CN106222155B (zh) 一种多肽及其在制备结肠炎及结肠炎相关结直肠癌药物中的应用
JP2008526189A5 (enExample)
WO2017075395A1 (en) Tumor-specific adenovirus vectors and therapeutic uses
CN112587654B (zh) 中脑星形胶质细胞源性神经营养因子在治疗溃疡性结肠炎中的应用
Moore-Carrasco et al. The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia
Xie et al. Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion
Li et al. p53 participates in the protective effects of ischemic post-conditioning against OGD-reperfusion injury in primary cultured spinal cord neurons
CN117836310A (zh) 细胞穿透肽、抗癌肽和包括其的用于预防或治疗癌症的药物组合物
Du et al. Adenovirus-mediated expression of Bm K CT suppresses growth and invasion of rat C6 glioma cells
JP2022023978A (ja) がんを治療するためのアデノウイルス及び化学療法剤の組合せ